Get the Weekly Intelligence Brief — top committee picks every Sunday.
ELV · NYSE · STOCK

Elevance Health (ELV) Stock Analysis

Healthcare Updated August 24, 2026
$402.93
52W $274.84 – $436.24
55/100
$86.86B
17.8
0.69
AI Committee Verdict
Watch
55/100
Conviction: Contested · 50% agreement · 6 analysts
+0.3%
-0.5%
0.66:1
Contested

Is ELV Bullish or Bearish?

Mixed. Innellis AI committee rates Elevance Health (ELV) Watch with a composite score of 55/100 , based on 6 analysts with 50% agreement. Last updated August 24, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +5.49 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -14.51 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Technical Analyst sees a compelling case — price structure making higher highs and higher lows. Risk Analyst remains cautious — current ratio of 0.19 is tight -- limited short-term liquidity cushion. This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • 4 consecutive earnings beats -- consistent execution — Growth
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
Bear Case
  • EPS declining -4.2% YoY despite any revenue growth — Growth
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
  • Current ratio of 0.19 is tight -- limited short-term liquidity cushion — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 24, 2026
Overall Committee Score
55/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 70%
of 192 Healthcare peers
Value Analyst neutral
58 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
Growth Analyst neutral
44 / 100 · High confidence
Moderate growth -- present but not remarkable
+ 4 consecutive earnings beats -- consistent execution
− EPS declining -4.2% YoY despite any revenue growth
Technical Analyst bullish
68 / 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
Risk Analyst bearish
35 / 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Current ratio of 0.19 is tight -- limited short-term liquidity cushion
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst neutral
58 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 3069.37)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 54.5 to 54.5.

Comparing 2026-08-23 to 2026-08-24 (1 day apart).

Technical Analysis

RSI (14)
59.7
Neutral
MACD Histogram
1.387
Bullish Momentum
Trend Direction
Uptrend
Weekly: Sideways
Market Structure
Mixed
Support
$398.52
Resistance
$402.04
Bollinger %B
0.80
Inside Bands
Price vs Moving Averages
EMA 9
$396.41 Above
EMA 21
$393.75 Above
EMA 50
$390.73 Above
EMA 200
$368.42 Above

Fundamental Analysis

Valuation
94
Growth
59
Profitability
43
Financial Health
95
Cash Flow
70
Valuation
P/E Ratio 17.8×
P/B Ratio 1.94×
PEG Ratio -3.96
Dividend Yield 1.71%
52W High $436.24
52W Low $274.84
Quality & Growth
ROE 1290.3%
ROA 466.0%
Gross Margin 3895.2%
Operating Margin 351.1%
Revenue Growth YoY
Debt / Equity 0.69
AI Fundamental Assessment
P/E ratio of 17.8 (inexpensive relative to a 15-40x range); Price-to-book of 1.9x; PEG ratio of -4.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 12.9%; Return on assets of 4.7%; Net margin of 2.5%; Gross margin of 39.0%; Current ratio of 2.05 (healthy short-term liquidity); Debt-to-equity of 0.69; Free cash flow per share is positive (28.86); Most recent quarter beat estimates by 18.9%; 4 consecutive earnings beats; EPS growth decelerating (+277.8% -> -40.8% QoQ); Average YoY EPS growth of -15.7%; Analyst estimates rising over recent quarters
Get the Full ELV Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime